# Anildeep Singh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anildeep-singh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 3 |
| i10-index | 0 |
| Last Known Institution | Johnson & Johnson (Singapore) |
| OpenAlex ID | https://openalex.org/A5102682923 |
| Works | 10 |

## Researcher papers

- [Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer-final-analysis/)
- [Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the <scp>TITAN</scp> trial: A post hoc analysis](https://scholariq.org/papers/prostate-specific-antigen-kinetics-in-asian-patients-with-metastatic-castration/)
- [Understanding Experiences and Needs of Patients With Prostate Cancer Across Asia-Pacific: A Cross-Sectional Mixed-Methods Study](https://scholariq.org/papers/understanding-experiences-and-needs-of-patients-with-prostate-cancer-across-asia/)
- [UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia](https://scholariq.org/papers/ufo-registry-final-analysis-of-baseline-data-from-patients-with-advanced/)
- [Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.](https://scholariq.org/papers/efficacy-and-safety-of-apalutamide-in-metastatic-castration-sensitive-prostate/)
- [Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study](https://scholariq.org/papers/niraparib-with-abiraterone-acetate-plus-prednisone-as-first-line-therapy-in/)
- [Clinical characteristics and treatment patterns of patients with high-risk localized prostate cancer (HR LPC) treated with radical prostatectomy (RP) and perioperative hormonal therapy (HT) in Japan, South Korea, and Taiwan.](https://scholariq.org/papers/clinical-characteristics-and-treatment-patterns-of-patients-with-high-risk/)
- [490MO Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) in Chinese patients with breast cancer susceptibility gene (BRCA) altered metastatic castration-sensitive prostate cancer (mCSPC): Subgroup analysis of the phase III AMPLITUDE trial](https://scholariq.org/papers/490mo-niraparib-nira-and-abiraterone-acetate-plus-prednisone-aap-in-chinese/)
- [515P Metastatic castration sensitive prostate cancer patient treatment preferences in China, South Korea and Japan](https://scholariq.org/papers/515p-metastatic-castration-sensitive-prostate-cancer-patient-treatment/)
- [Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer.](https://scholariq.org/papers/evaluation-of-psa-decline-patterns-in-the-chinese-subgroup-of-libertas-a-phase-3/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)

## Researcher university

- [Johnson & Johnson (Singapore)](https://scholariq.org/institutions/johnson-and-johnson-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.